Synthesis of the intermediate
II-x II-ix Scheme S1. The synthesis of the intermediates
5-(4-chlorophenyl) furan-2-carbaldehyde (1) 1
A mixture of 4-chloroaniline (2.55 g, 20 mmol), concentrated hydrochloric acid (14 mL), and water (20 mL) was heated to get a clear solution. The solution was cooled to 0 °C and was diazotized by the addition of sodium nitrite solution (13.8%, 10 mL). The cold clear solution of the diazonium salt was collected by filtration and was treated with 2-furfuraldehyde (2.88 g，30 mmol) and an aqueous solution of CuCl 2 (0.54 g in 2 mL of water). Then, the reaction mass was stirred at room temperature overnight and filtrated to afford brown solid. Then, the crude product was recrystallized in ethanol to afford 1 as a light brown solid in 25.4%
yield. 1 
(E)-1-(((5-(4-chlorophenyl) furan-2-yl) methylene) amino) imidazolidine-2,4-dione (2)
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A mixture of 1-aminohydantoin hydrochloride (0.30 g, 2 mmol) and compound 1 (0.21 g, 1 mmol) in water (6 mL) was stirred at 80°C for 4 h. The reaction suspension was filtrated, washed with water and dried to afford 2 as a pale pink solid in 89.1% yield. To a solution of compound 6 (2.00 g, 10.14 mmol) and anhydrous potassium carbonate (5.59 g, 40.56 mmol) in 20 mL acetonitrile, 1,3-dibromopropane (6.14 g, 30.43 mmol) was added and the mixture was refluxed for 12 h. Then, the reaction mixture was filtrated, and the filtrate was concentrated in vacuo. The crude product was further purified by silica gel chromatography (eluent: 
2-(4-bromobutyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (7b)
The compound 7b was prepared following the method described for the preparation of compound 7a, employing compound 6 (2.00 g, 10.14 mmol) and 1, 
N-(1,3-dioxo-1,3-dihydrobenzo[de]isochromen-6-yl)acetamide (13)
A mixture of compound 12 (0.90 g, 2.3 mmol), acetic acid (1 mL), and pyridine (4 mL) was refluxed for 1 h. Then, acetic anhydride (8 mL) was added, and the refluxing was continued 3 h. The resulting mixture was poured into water, and the precipitation filtrated and washed with water to afford compound 10 as a brown solid in 67.2%.
N-(2-(4-hydroxybutyl)-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin-6-yl)acetamide (14a)
The compound 14a was prepared following the method described for the preparation of compound 9, employing compound 13
(1.00 g, 3.91 mmol) and 4-amino-1-butanol (0.42 g, 4.70 mmol), and the product 14a was afford as a brown solid in 50.78% yield. 
N-(2-(6-hydroxyhexyl)-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin-6-yl)acetamide (14b)
The compound 14b was prepared following the method described for the preparation of compound 9, employing compound 13
(1.00 g, 3.91 mmol) and 6-amino-1-butanol (0.46 g, 4.70 mmol), and the product 14b was afford as a brown solid in 51.08% yield. 
N-(2-(4-bromohexyl)-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin-6-yl)acetamide (15a)
The compound 15a was prepared following the method described for the preparation of compound 10, employing compound 14a (0.61 g, 1.87 mmol) and PBr 3 (0.60 mL), and the product 15a was afford as a brown solid in 83. 
N-(2-(6-bromohexyl)-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin-6-yl)acetamide (15b)
The compound 15b was prepared following the method described for the preparation of compound 10, employing compound 14b 
2-(2-(piperazin-1-yl)ethyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (18a)
A mixture of compound 10 (0.20 g, 0.66 mmol), tert-butyl piperazine- 
Tert-butyl 4-(3-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)propyl)piperazine-1-carboxylate (11b)
The compound 11b was prepared following the method described for the preparation of compound 11a, employing compound 7a (0.50 g, 1.57 mmol), K 2 CO 3 (0.43 g, 3.14 mmol) and tert-butyl piperazine-1-carboxylate (0.44 g, 2.36 mmol), and the crude product was purified by silica gel chromatography (eluent: 0%-12.5% CH 2 Cl 2 in methanol) to afford compound 11b as a white solid (pure) 
2-(3-(piperazin-1-yl)propyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (18b)
Trifluoroacetic acid (0.8 mL) was added to a solution of compound 11b (0.34 g, 0.80 mmol) in CH 2 Cl 2 (3 mL), and the reaction mixture was stirred at room temperature for 6 h. The mixture was basified with saturated aqueous solution of NaHCO 3 .and extracted with CH 2 Cl 2 (40 mL). The combined organic layer was dried over anhydrous MgSO 4 , filtered and concentrated under reduced pressure to afford compound 18b as white solid in 80.0% yield.
Tert-butyl 4-(4-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)butyl)piperazine-1-carboxylate (11c)
The compound 11c was prepared following the method described for the preparation of compound 11a, employing compound 7b 
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2-(4-(piperazin-1-yl)butyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (18c)
The compound 18c was prepared following the method described for the preparation of compound 18b, employing compound 11c (0.20 g, 0.46 mmol) and trifluoroacetic acid (0.8 mL), and get compound 18c as a white solid in 73.3% yield.
N-(1,3-dioxo-2-(2-(piperazin-1-yl)ethyl)-2,3-dihydro-1H-benzo[de]isoquinolin-6-yl)acetamide (18d)
A mixture of compound 13 (0.30 g, 1.18 mmol) and 1-(2-aminoethyl)-piperazine (0.18 g, 1.41 mmol) in 15 mL ethanol was refluxed for 2 h and then the solvent was removed in under vacuum. The crude product was purified by silica gel chromatography 
6-(dimethylamino)-2-(2-(piperazin-1-yl)ethyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (18e)
The compound 18e was prepared following the method described for the preparation of compound 18d, employing compound 17 (0.20 g, 0.83 mmol) and 1-(2-aminoethyl)-piperazin (0.14 g, 1.08 mmol). The crude product was purified by silica gel 5, 6 HEK 293 cell line stably transfected with hERG gene was obtained as a gift from the Li group at the University of Hong Kong and cultured in Dulbecco's modified eagle's medium (DMEM) supplemented with 10% fetal bovine serum and 400 μg/mL G418 (Sigma). The establishment of the hERG-transfected HEK293 cell line was described in their previous paper. 7 Briefly, the vector of hERG/pcDNA3 generously provided by Dr. G. Robertson (University of Wisconsin, Madison, WI, USA) was transfected into HEK 293 cells (ATCC, Manassas, VA, USA) using 10 ml Lipofectamine 2000TM (Invitrogen, Hong Kong) with 4 mg hERG/pcDNA3 plasmid, and selected using 1000 mg/ml G418 (Sigma-Aldrich, St. Louis, MO). Colonies were picked with cloning cylinders and examined for channel expression by whole-cell current recordings as previously reported. 8 The significant tail current of hERG channel was observed.
Absorption and emission spectra of probes
Cell membrane preparation
As we know, although the hERG-HEK293 we use was a stably transfected cell line, with the cells passaged, the transfected gene may be lost. Therefore, to guarantee the quality of the extracted cell membrane, we examined the hERG channel current changes with the increase of the cell generation. The results showed that the hERG channel current was weak after about 6 times of passages. Therefore, to obtain cell membrane pellets for PET assay and FP assay, we only collected membrane from the first S7
